STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show

STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show
STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. The findings were presented by Wendel Naumann, MD, principal investigator of the trial, in a recent virtual presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting. Sutro Biopharma’s STRO-002 contains an antibody that specifically binds to folate receptor alpha (FRα), a protein found in high levels in most types of ovarian cancer. This prompts the release of a toxic compound to kill tumor cells, while sparing healthy cells. The safety, tolerability, and preliminary efficacy of STRO-002 are being evaluated in an open-label Phase 1 trial (NCT03748186) in heavily pre-treated women with recurrent platinum-resistant or refractory ovarian cancer (including
Subscribe or to access all post and page content.